Triomics
YC W21New York City, US · Founded 2021 · Delaware corporation · 50 employees · Hiring · 8 known investors
Triomics builds AI systems for oncology teams that read full patient records and produce structured, auditable outputs for trial matching, visit preparation, and data curation. The company serves oncology clinics, trial matching networks, and quality reporting teams.
Also known as Triomics Healthcare Private Limited · Triomics
Founders & leadership· Y Combinator alumni (W21)
Triomics was founded in 2021 by Sarim Khan and Hrituraj Singh.
Board
Investors · 8
.png)
Also in the syndicate · 2
Funding
SEC filings, press & company announcements$35.8M disclosed across 2 of 3 rounds · 2022–2026
- $22MraisedJun 2026 · 4 sources
Battery (lead), Battery Ventures, Lightspeed, Nexus Venture Partners, Oncology Ventures, Precision Health Informatics, Y Combinator
Source ↗ - Undisclosed amountSeries AMay 2024
General Catalyst, Lightspeed, Nexus Venture Partners, Y Combinator
Source ↗
▶$13.8MraisedFeb 2023 · 10 investors · Other TechnologyRule 506(b)
- Devtosh Kumar KhareDirector
- Sameer Brij VermaDirector
- Hrituraj SinghDirector
- Sajjan RajpurohitDirector
- Sarim KhanExecutive Officer, Director
- Offering amount
- $14.1M
- Amount sold
- $13.8M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026Triomics develops AI software for cancer care workflows. Its platform applies AI agents, including a model the company calls OncoLLM, to reason across the entirety of a patient's oncology record — clinical notes, pathology, imaging, molecular reports and scanned faxes spanning years — and to return structured answers with citations linked back to the specific line in the record.
The product covers three principal workflows. Patient trial matching screens every patient on a clinic's schedule against every active trial and produces a prioritized, evidence-cited candidate worklist for research coordinators. Visit preparation and pre-charting assembles a patient snapshot covering disease status, treatment timeline and biomarkers, and drafts a pre-charting note in the physician's preferred format inside the EMR. Cancer registry curation generates structured abstractions aligned to NAACCR, SEER, CoC and QOPI measures, with each field traceable to its chart source. Audit trails and source citation are described as built into every output rather than added on.
Business model
Triomics sells a software platform to cancer centers and oncology practices, deployed inside existing clinical systems and covering multiple oncology workflows on a single platform.
Traction
The company reports reading roughly 120,000 charts per month and screening more than 65,000 patients for trials monthly, along with more than ten NCI-designated customers. Reported outcome figures include a 70% reduction in chart review time, a 30% lift in trial accruals and 40% more matches generated (from an ASCO 2025 abstract co-authored with an academic medical center), 80% and 45% reductions in pre-charting time for new and follow-up visits respectively (community oncology practice case study), and 96% abstraction accuracy with 75% faster case abstraction and 60% faster case finding (preprint on structuring unstructured medical records).
Latest developments
Company posts describe Memorial Sloan Kettering deploying the Triomics platform for clinical trial matching and screening (October 2025), an implementation of AI cancer clinical-trial screening to improve access in Connecticut (November 2025), Mount Sinai launching an AI-powered clinical trial-matching platform (January 2026), and work evaluating AI-enabled trial screening in real-world oncology workflows (February 2026).
▸Full profile — market position, technology, go-to-market
Market position
Triomics states that four of the top ten U.S. cancer centers use its platform and that it has more than ten NCI-designated customers, positioning itself against general-purpose medical AI that processes records page by page.
Triomics emphasizes whole-chart reasoning rather than page-level processing, clinically traceable outputs where every field or match carries a clickable citation and built-in audit trails, native handling of common healthcare data and document formats, and delivery inside existing EMR workflows.
Technology
The core component is OncoLLM, which reasons across hundreds of pages of a longitudinal patient record instead of processing single pages. The system ingests and normalizes HL7, FHIR, CCDA, PDF, TIFF and JPEG inputs natively and runs inside electronic medical record systems including Epic, OncoEMR and iKnowMed; the application is approved on the Epic App Marketplace. Outputs carry clickable source citations back to the underlying record.
Go-to-market
The company markets directly to cancer centers, offering a 30-minute working session with a synthetic-data sandbox or, under a business associate agreement, with the customer's own data. It also publicizes named deployments at academic medical centers and publishes case studies, abstracts and preprints on accuracy and workflow impact.
Academic and NCI-designated cancer centers, community oncology practices, clinical research coordinator and trial screening teams, physicians, medical assistants, and cancer registry and quality reporting staff.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Competitors · 5
by search overlap
Companies competing with Triomics for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 5
launches, deals, and filingsCompany post covering evaluation of AI-enabled trial screening in real-world oncology workflows.
The platform runs inside EMRs including Epic, OncoEMR and iKnowMed and is approved on the Epic App Marketplace.
Company post announcing Mount Sinai's launch of an AI-powered clinical trial-matching platform to expand access to cancer research.
Company post describing implementation of AI-enabled cancer clinical-trial screening to improve trial access in Connecticut.
Company post announcing that Memorial Sloan Kettering will deploy Triomics' AI platform to improve clinical trial matching and screening.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
Legal entities · 1
corporate structureIn the news
▸Research sources · 1
primary sources listed
- Triomicstriomics.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Triomics do?
- Triomics builds oncology AI agents that read full patient charts to support trial matching, visit prep, and registry curation.
- Who founded Triomics?
- Triomics was founded by Sarim Khan, Hrituraj Singh in 2021.
- Who are Triomics's investors?
- Triomics's investors include Battery Ventures, Y Combinator, Lightspeed Venture Partners, Oncology Ventures, General Catalyst, Nexus Venture Partners.
- How much funding has Triomics raised?
- Triomics has disclosed $35.8M raised across 2 of its 3 known rounds.
- Where is Triomics headquartered?
- Triomics is headquartered in New York City, US.